Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger that will move the public company away from its original oncology focus and toward antibodies for inflammatory disease. The deal comes with a $120 million private placement in Bolt and the possibility of another $60 million if warrants are exercised, giving the combined company fresh capital alongside a new pipeline.
The investor syndicate includes Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Eventide Asset Management, Casdin Capital and Soleus Capital, among others. According to Bolt’s Oct. 23 release, the financing is expected to extend the company’s cash runway into 2028.
The pipeline being bought
Prana is contributing its INSPIRE platform and lead bispecific antibody PRA-216. The drug blocks interleukin-4 receptor alpha and thymic stromal lymphopoietin, two nodes in type 2 inflammation. TSLP is an epithelial alarmin, while IL-4Rα mediates signaling by IL-4 and IL-13.
PRA-216 is already in phase 2 development for asthma, chronic obstructive pulmonary disease and atopic dermatitis. Prana is also planning a phase 2 study in eosinophilic esophagitis. The company said patient data from all four trials are expected between the second and fourth quarters of 2027.
Why the deal matters for Bolt
The merger is also a reset for Bolt. The company launched in 2015 with a focus on cancer and raised $230 million in an upsized IPO in 2021. That strategy ran into trouble in 2022, when off-target toxicity led to the axing of an immune-stimulating antibody candidate. Since then, Bolt has gone through multiple workforce reductions over a two-year span.
Bolt still has collaborations with Genmab and Toray focused on cancer immune-stimulating antibody conjugates, but this transaction makes clear where new capital is being directed. Rather than financing a long rebuild around older oncology programs, investors are backing a later-stage inflammation asset with multiple phase 2 shots on goal in 2027. That is the more immediate signal in the reverse-merger market: public biotech shells are still valuable when they can be paired with capital and a pipeline that is closer to clinical inflection points.
